Commercialization of Organ Transplants: Ethics and Policy

Introduction

Organ transplantation is one of the greatest advances in modern medicine. It is an operation in which an organ is removed from one person (the donor) and transferred to another (the recipient or patient). From its inception, a fundamental dispute has existed regarding whether organs should be sold or obtained exclusively through voluntary donation. Both the sale of organs and donation-only systems present distinct advantages and disadvantages, ultimately raising the question of what approach is safest and most beneficial for humanity. This report examines the primary arguments on both sides of this debate, along with relevant scientific and ethical information.

Currently, organ transplantation is not a legal, profitable market in most countries. However, a black market for organ selling exists, characterized by exorbitant costs and dangerous acquisition methods. In the United States, there is a National Donor waiting list for patients who qualify for transplantation. A patient with terminal organ failure may qualify for a transplant if they are free from cancer and active infection. Once approved, patients are placed on the National Donor list and must await their turn. The demand for organs far exceeds the supply of available donors. To become an organ donor, a person may designate themselves as a donor on their driver's license or inform family members of their wishes. Additionally, living donors may contribute certain organs, such as a kidney or partial liver.

The question of organ commercialization divides people along ethical, moral, and economic lines. Some oppose it on ethical or moral grounds, while others are motivated by the potential market profit. Understanding these competing perspectives is essential to evaluating the viability and desirability of an organ market.

Arguments for Organ Commercialization

Supporters of legalizing organ sales, though a minority, present compelling arguments. The primary claim is that permitting the buying and selling of organs would increase the supply of available organs for transplant. Currently, the waiting list grows each year while the donor pool remains static. Transplant surgeons advocating for legalization argue that a regulated commercial market would allow people to make more informed decisions on an issue with significant moral and medical importance. In 2011, approximately 8,000 people were on the waiting list, with over 500 dying annually before their name came up for transplant (Smith, 2011). Proponents believe that a regulated market for organs could substantially reduce, if not eliminate, the use of dangerous black markets (Smith, 2011).

Arguments Against Organ Commercialization

Opponents of organ commercialization raise several critical concerns. They argue that donors' safety would be compromised, that financial incentives would unfairly appeal to economically disadvantaged populations, that the human body would become merely a profit-generating commodity, and—most prominently—that wealthy individuals would gain faster access to organs than less fortunate people. Experts contend that if organ sales were legalized, poor and uneducated populations would likely become the primary sellers, using organ donation as a survival mechanism. Conversely, wealthy individuals would secure organs more quickly and easily, creating a system of inequality. Medical ethicists argue that the buying and selling of organs is fundamentally unethical and morally indefensible (Ehtuish, 2011, p. 64).

Balancing Pros and Cons

The advantages of commercializing organ sales are limited but noteworthy. Legalizing organ sales would increase the supply of available organs for transplant. It would illuminate and diminish black market activity, making organ donation safer for participants. Black market organ trafficking sometimes results in violent crimes and murder as criminals resort to extreme measures to obtain organs. Compensated donors could participate in legal markets alongside voluntary donors.

The disadvantages of organ commercialization are more substantial and tend to capture public concern more readily. The sale of organs would likely exploit poor and uneducated populations. Offering financial compensation for organ donation raises serious moral and ethical concerns about coercion and human dignity. Under current donor programs, all donors must be in excellent health; commercialization might incentivize donors to conceal illnesses or health issues to qualify for payment, potentially resulting in infected or compromised organs. This could cause deaths among both donors and transplant recipients. Furthermore, legalizing organ sales would undermine existing legal frameworks and donation programs that have taken decades to establish.

Ethical Framework and Personal Position

Based on available research and personal moral judgment, commercializing human organs is not ethically justified. People will pursue extreme measures to obtain organs for themselves or their loved ones, and the black market remains a costly and unsafe alternative. Documented cases show that individuals have committed violence and even murder to acquire organs for transplant or for sale on the black market. Legalizing organ sales would likely increase deaths overall and paradoxically reduce the organs available for transplant by deterring altruistic donors.

Consequentialist ethical theory provides a framework for this judgment. This theory holds that the moral rightness or wrongness of an action is determined by its overall consequences. An act is morally right if it produces more good outcomes than bad; conversely, it is morally wrong if negative consequences outweigh positive ones. Applied to organ commercialization, the theory suggests that because the harms—exploitation, reduced voluntary donation, health risks, and inequality—are more substantial than the benefits, the practice would be morally wrong (Shaw, 2014, p. 42–43). For organ sales to be morally justified under consequentialism, they would need to produce substantially more organs and save more lives than the current donation system, outcomes that the evidence does not support.

Conclusion

As with any policy debate, compelling arguments exist on both sides. The question of organ commercialization has been debated for many years but has remained illegal in most countries. There are no indications that legislators will change current laws, as policymakers broadly agree that existing organ donation and transplant programs function effectively. Rather than legalizing organ sales, society should invest in education about both living and deceased organ donation. Increased awareness and understanding of donation options would likely raise donation rates and expand the available organ supply without the ethical costs of commercialization. I do not believe that selling human organs should be commercialized, as the risks and ethical harms significantly outweigh the potential benefits.